The small-molecule inhibitors calyculin A and okadaic acid have been used to mitigate PP1 and PP2A activity, thereby impairing the progression of hormone therapy-resistant prostate cancer by stimulating cell death59. The gene discussed is PTPA; the disease is prostate carcinoma.